Victory Capital Management
AMRX icon

Victory Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Victory Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.03M Buy
521,888
+59,914
+13% +$821K 0.01% 1162
2026
Q1 		$5.74M Buy
461,974
+443,923
+2,459% +$5.96M ﹤0.01% 1275
2025
Q4 		$227K Buy
18,051
+1,351
+8% +$15.5K ﹤0.01% 2172
2025
Q3 		$167K Sell
16,700
-419
-2% -$3.76K ﹤0.01% 2244
2025
Q2 		$138K Sell
17,119
-343,710
-95% -$2.59M ﹤0.01% 2299
2025
Q1 		$3.02M Buy
360,829
+149,699
+71% +$1.25M ﹤0.01% 1430
2024
Q4 		$1.67M Buy
211,130
+111,915
+113% +$939K ﹤0.01% 1572
2024
Q3 		$825K Buy
99,215
+36,700
+59% +$287K ﹤0.01% 1853
2024
Q2 		$397K Sell
62,515
-90,568
-59% -$575K ﹤0.01% 2032
2024
Q1 		$928K Sell
153,083
-142,615
-48% -$804K ﹤0.01% 1779
2023
Q4 		$1.79M Sell
295,698
-13,534
-4% -$60.3K ﹤0.01% 1455
2023
Q3 		$1.3M Buy
309,232
+406
+0.1% +$1.51K ﹤0.01% 1529
2023
Q2 		$957K Sell
308,826
-255
-0.1% -$543 ﹤0.01% 1703
2023
Q1 		$430K Buy
309,081
+69,360
+29% +$138K ﹤0.01% 2040
2022
Q4 		$477K Buy
239,721
+44,457
+23% +$99.7K ﹤0.01% 2025
2022
Q3 		$394K Sell
195,264
-629,924
-76% -$1.77M ﹤0.01% 2151
2022
Q2 		$2.62M Sell
825,188
-385,163
-32% -$1.4M ﹤0.01% 1392
2022
Q1 		$4.98M Buy
1,210,351
+30,700
+3% +$136K 0.01% 1298
2021
Q4 		$5.65M Buy
1,179,651
+170,018
+17% +$848K 0.01% 1298
2021
Q3 		$5.39M Sell
1,009,633
-911,857
-47% -$4.59M 0.01% 1312
2021
Q2 		$9.84M Buy
1,921,490
+133,828
+7% +$761K 0.01% 1136
2021
Q1 		$12M Buy
1,787,662
+1,616,423
+944% +$8.96M 0.01% 1086
2020
Q4 		$783K Buy
171,239
+73,602
+75% +$326K ﹤0.01% 1888
2020
Q3 		$379K Buy
97,637
+50,815
+109% +$217K ﹤0.01% 2068
2020
Q2 		$223K Sell
46,822
-1,383
-3% -$5.7K ﹤0.01% 2270
2020
Q1 		$168K Sell
48,205
-6,903
-13% -$29.2K ﹤0.01% 2203
2019
Q4 		$266K Buy
55,108
+5,066
+10% +$17.6K ﹤0.01% 2233
2019
Q3 		$145K Buy
+50,042
New +$175K ﹤0.01% 2316

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Victory Capital Management's AMRX Position: Q2 2026 in Review

Victory Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 13% in Q2 2026, buying an estimated $821K and bringing the position to 521,888 shares worth $9.03M. The position accounts for 0.01% of the portfolio, ranked #1162.

Victory Capital Management first reported a position in AMRX in Q3 2019 and has held it in 28 quarters since. The position peaked at $12M in Q1 2021. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Victory Capital Management held 521,888 shares of Amneal Pharmaceuticals worth $9.03M as of Q2 2026.
  • Victory Capital Management bought 59,914 Amneal Pharmaceuticals shares in Q2 2026, an estimated $821K.
  • Amneal Pharmaceuticals made up 0.01% of Victory Capital Management's portfolio in Q2 2026, its #1162 holding.
  • Victory Capital Management first reported a position in Amneal Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Amneal Pharmaceuticals position peaked at $12M in Q1 2021.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.